MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer, will join a number of employees to ring the Nasdaq Opening Bell for the 14th consecutive year on October 2 to mark the start of Breast Cancer Awareness Month.
Hologic, the pioneer behind 3D mammography and the maker of the Genius™ 3D Mammography™ exam, the first breast tomosynthesis exam approved by the FDA in 2011, has expanded its product portfolio significantly in recent months through insight-driven innovation and strategic acquisitions to address the entire continuum of breast cancer diagnosis and care. From tomosynthesis to ultrasound, to digital specimen radiography and stereotactic breast biopsy systems, to breast biopsy markers and surgical guidance systems – Hologic’s comprehensive suite of products is designed to meet the needs of radiologists, pathologists, breast surgeons and patients.
“As the world leader in mammography and a company focused on women’s health, we’re committed to early detection, more certain diagnoses, and accurate and compassionate treatment for women facing breast cancer,” said MacMillan. “We’re proud to recognize Breast Cancer Awareness Month by ringing the Nasdaq Opening Bell for the 14th year in a row, and we’re grateful to be joined by many of the dedicated employees whose passion fuels the work we do.”
Along with the Genius exam, which detects 20-65 percent more invasive breast cancers and is the only mammogram approved by the FDA as superior for all women, including those with dense breasts, Hologic continues to develop and introduce a number of innovations designed to improve the clinician and patient experience at every stage of the breast health journey.1,2
One of these innovations, the SmartCurve™ breast stabilization system, is a more comfortable mammogram that features a proprietary curved surface that mirrors the shape of a woman’s breast to reduce pinching and allow better distribution of force over the entire breast. In a clinical study compared to standard compression, the SmartCurve system improved comfort in 93 percent of women who reported moderate to severe discomfort with standard compression.3 In addition, Hologic recently added to its breast surgery portfolio the BioZorb® marker, a bioabsorbable three-dimensional marker that potentially enables more targeted radiation therapy and helps clinicians overcome challenges in breast conserving surgery or lumpectomy.
The Genius™ 3D Mammography™ exam (also known as the Genius™ exam) is only available on a Hologic® 3D Mammography™ system. It consists of a 2D and 3D™ image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™ image set. There are more than 6,000 Hologic 3D Mammography™ systems in use in the United States alone, so women have convenient access to the Genius exam. To learn more, visit http://www.Genius3DNearMe.com.
Hologic’s participation in the Nasdaq opening bell ceremony will be aired live at https://new.livestream.com/NASDAQ/live and with closed captioning on the Nasdaq MarketSite tower in Times Square. A video of the ceremony will be archived for one year on the Nasdaq site.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, 3D, 3D Mammography, 3Dimensions, BioZorb, Genius, SmartCurve and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to firstname.lastname@example.org.
SOURCE: Hologic, Inc.
1 Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions® on screening outcomes. Individual results may vary. The study found an average 41% increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1,000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
2 FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005.
3 Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00019 Rev 003 (2017).